[8-K] Protalix BioTherapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Meta Platforms (NASDAQ: META) founder & CEO Mark Zuckerberg has filed a Form 144 signaling his intent to sell 15,847 Class A shares (estimated value ≈ $11.94 million) on or about 1 Aug 2025 via Charles Schwab. The filing follows 16 insider sales executed between 6 Jun – 31 Jul 2025 totaling 156,847 shares and roughly $113 million in gross proceeds. Planned and completed sales combined equal just 0.007% of META’s 2.17 billion shares outstanding.

The shares were originally obtained through an option exercise dated 17 May 2012. As required by Rule 144, the notice affirms the seller holds no undisclosed material adverse information and makes no reference to a Rule 10b5-1 trading plan. While the transaction is immaterial to the company’s capital structure, it extends a steady pattern of founder share liquidation that investors may monitor for sentiment clues.

Positive

• Sale represents only ~0.007 % of shares outstanding, implying negligible dilution or market overhang.
• Transparent Rule 144 filing demonstrates adherence to disclosure requirements, reducing regulatory risk.

Negative

• Founder has liquidated ~$113 m of stock in the last three months, a potential negative sentiment signal.
• No 10b5-1 plan disclosed, leaving timing decisions open to interpretation and potential governance critique.

Insights

Portfolio Manager

TL;DR: Small-scale founder sale; sentiment watch, but negligible dilution.

The proposed 15.8k-share sale adds to 156.8k shares already liquidated this summer, bringing Zuckerberg’s 3-month cash out to ~$125 m when the next trade settles. Even combined, this equals <0.01 % of META’s float, so supply overhang is minimal. Insider diversification is common and does not signal operational weakness. I see neutral market impact; valuation should hinge on fundamentals, not this filing.

Corporate Governance Analyst

TL;DR: Continued insider selling may raise optics questions despite immaterial size.

Zuckerberg controls ~58 % voting power; repeated cash sales without accompanying 10b5-1 detail can attract scrutiny over information asymmetry. Although Rule 144 compliance is clear, cumulative sales above $100 m in three months could be construed as waning confidence. Visibility into any pre-arranged plan would ease concerns. I assign a mild negative governance signal, yet note no change in control risk.

0001006281false00010062812025-08-012025-08-01

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 1, 2025

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware		001-33357		65-0643773
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)
​	​	​	​	​
2 University Plaza	​	​	​	​
Suite 100	​	​	​	​
Hackensack, NJ	​	​	​	07601
(Address of principal executive offices)	​	​	​	(Zip Code)

​

 Registrant’s telephone number, including area code 201-696-9345

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.001 par value	PLX	NYSE American

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

​

​

Item 8.01 Other Events

​

On August 1, 2025, Protalix BioTherapeutics, Inc. (the “Company”) announced the dismissal of a claim against the Company and its Board of Directors (the “Board”). On March 10, 2025, plaintiff Kevin Mathew Thomas (“Plaintiff”) filed a Verified Stockholder Class Action Complaint (the “Complaint”) in the Court of Chancery of the State of Delaware against the Company and the members of its Board, captioned Thomas v. Bashan, et al., C.A. No. 2025-0259- PAF (the “Action”). In the Action, Plaintiff alleged that certain provisions in the Amended and Restated Bylaws of Protalix BioTherapeutics, Inc. (as adopted on December 27, 2024, the “Bylaws”) violated the terms of 8 Del. C. §§ 141(k) & 228(a). While the Company and the Board deny completely all of the allegations of wrongdoing in the Complaint, on May 8, 2025, the Board amended the Bylaws. As a result of this amendment of the Bylaws, Plaintiff agreed that his claims were moot, and the Company agreed to pay $160,000 in fees and expenses to Plaintiff’s counsel. On July 23, 2025, the Court entered a Stipulation and Order providing that Plaintiff’s Action would be dismissed with prejudice only as to Plaintiff and the case will be closed. The Court has not passed on the amount of fees and expenses. Plaintiff’s Counsel are Fields Kupka & Shukurov LLP, (212) 231-1500, ATTN: Christopher J. Kupka. Defendants’ Counsel are Mayer Brown LLP, (212) 506-2500, ATTN: Henninger S. Bullock.

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 1, 2025	PROTALIX BIOTHERAPEUTICS, INC. ​ ​
	By:	/s/ Dror Bashan
		Name:	Dror Bashan
		Title:	President and Chief Executive Officer

​

​

FAQ

How many Meta (META) shares is Mark Zuckerberg planning to sell?

The Form 144 covers 15,847 Class A shares with an estimated value of $11.94 million.

What percentage of Meta's outstanding shares does the proposed sale represent?

Only about 0.007 % of the 2.17 billion shares outstanding.

How many shares has Zuckerberg sold in the past three months?

He has already sold 156,847 shares between 6 June and 31 July 2025.

What were the gross proceeds from recent insider sales?

The past three-month sales generated approximately $113 million in gross proceeds.

When were the shares originally acquired?

The shares were acquired via option exercise on 17 May 2012.

Is the upcoming sale under a Rule 10b5-1 trading plan?

The filing does not reference any Rule 10b5-1 plan.